Systane Balance
PreclinicalSmall molecule
Systane Balance is one of 6 small molecule programs targeting Meibomian Gland Dysfunction. It is currently in Preclinical.
1
Indications
3
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Meibomian Gland Dysfunction
#DrugCompanyPhaseTrials
1Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Vevye
RochePhase 3
Liposic
SSun Yat-sen University
Preclinical
Tears Naturale Forte
SSun Yat-sen University
Preclinical
Systane Balance
LLaboratorios Sophia S.A de C.V.
Preclinical
Oral Administration of Lobeglitazone
YYonsei University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Meibomian Gland Dysfunction1 trial
The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction
Completed·SSouthern California College of Optometry at Marshall B. Ketchum University·N/A·NCT01207752·69 enrolled
Efficacy and Safety1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Systane Balance. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- LLaboratorios Sophia S.A de C.V.